Dynavax to Present at the 3rd Annual Evercore Virtual ISI HealthCONx Conference

Dynavax Technologies Corporation (NASDAQ: DVAX) will have CEO Ryan Spencer participate in a virtual fireside chat at the 3rd Annual Evercore Virtual ISI HealthCONx Conference on December 3, 2020, at 10:05 a.m. E.T.

Rhea-AI Summary

Dynavax Technologies Corporation (NASDAQ: DVAX) will have CEO Ryan Spencer participate in a virtual fireside chat at the 3rd Annual Evercore Virtual ISI HealthCONx Conference on December 3, 2020, at 10:05 a.m. E.T. The event will be accessible via the company's website under the 'Events & Presentations' section. A replay will be available for 30 days post-event. Dynavax is developing innovative vaccines, including its first commercial product, HEPLISAV-B, aimed at preventing hepatitis B infections in adults.

Argus Session date unavailable

-4.99% session move Open Argus

Details

News Market Reaction – DVAX

The recorded move for DVAX in the trading session of this news was -4.99%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

EMERYVILLE, Calif., Nov. 17, 2020 /PRNewswire/ -- Dynavax Technologies Corporation (NASDAQ: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the 3rd Annual Evercore virtual ISI HealthCONx Conference on Thursday, December 3, at 10:05 a. m. E.T.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at www.dynavax.com. A replay of the webcast will be available for 30 days following the live event.

About Dynavax
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018 as a premier vaccine adjuvant through global research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza. For more information, visit www.dynavax.com and follow the company on LinkedIn.

Contacts:

Nicole Arndt, Senior Manager, Investor Relations
narndt@dynavax.com 
510-665-7264

Derek Cole, President
Investor Relations Advisory Solutions
derek.cole@IRadvisory.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/dynavax-to-present-at-the-3rd-annual-evercore-virtual-isi-healthconx-conference-301175311.html

SOURCE Dynavax Technologies

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is Dynavax Technologies Corporation's announcement on November 17, 2020?

Dynavax announced that CEO Ryan Spencer will participate in a virtual fireside chat on December 3, 2020, at the 3rd Annual Evercore Virtual ISI HealthCONx Conference.

When is Ryan Spencer speaking at the Evercore conference?

Ryan Spencer will speak at 10:05 a.m. E.T. on December 3, 2020.

How can I listen to the Dynavax conference presentation?

The presentation can be accessed through the 'Events & Presentations' page on the Investors section of Dynavax's website.

What is HEPLISAV-B, Dynavax's product?

HEPLISAV-B is a hepatitis B vaccine approved in the U.S. for preventing infections caused by all known subtypes of hepatitis B virus in adults aged 18 and older.

What collaborations is Dynavax involved in regarding vaccines?

Dynavax is working on collaborations focusing on adjuvanted vaccines for COVID-19, pertussis, and universal influenza.